Related by context. All words. (Click for frequent words.) 68 FEV1 66 Pharmacokinetic parameters 66 fasting plasma glucose FPG 65 ADAS cog 64 postdose 64 8mg/kg 63 oxycodone CR 63 -#.# mg dL [001] 63 HBeAg seroconversion 63 Demonstrate Significant 63 calculated creatinine clearance 63 Psoriasis Area 63 Montgomery Asberg Depression 63 alanine aminotransferase ALT 62 International Prostate Symptom 62 Oral Fingolimod 62 ACR# response 62 Capacity FVC 62 Forced Vital 62 Index CDAI 62 Score IPSS 62 mg TID 62 lumbar spine BMD 62 HAQ DI 62 QTcF 62 achieved statistical significance 62 mcg QD 62 -#.# mg dL [002] 62 Rating Scale MADRS 62 Crohn Disease Activity 62 ACR# responses 62 desvenlafaxine succinate 62 serum phosphorous 61 hematological parameters 61 Fasting blood glucose 61 mcg BID 61 virologic response 61 pharmacokinetic PK profile 61 PASI scores 61 LANTUS R 61 #mg/day [001] 61 MARINOL R 61 tolterodine ER 61 -#.# log# 61 moderate renal impairment 61 Acetate Rectal Suppositories 61 fosamprenavir 61 plus methotrexate 61 Scale cognitive subscale 61 Demonstrated Significant 61 Alzheimer Disease Assessment 61 fasting plasma glucose 61 Relapsing Multiple Sclerosis 61 peak expiratory flow 61 ACTEMRA TM 60 #μg [002] 60 serum urate 60 CIMZIA TM 60 6MWD 60 ADAS Cog 60 Negative Syndrome 60 bortezomib refractory 60 alanine aminotransferase 60 -#.# log# copies mL 60 PANSS total 60 placebo p 60 paricalcitol 60 spirometric 60 SVR# 60 -#.# mmHg 60 morphometric vertebral fractures 60 lumbar spine bone 60 Tasigna prolongs 60 serum potassium 60 Unified Parkinson Disease 60 CYP#A# substrate 60 peak VO2 60 demonstrated clinically meaningful 60 abacavir lamivudine 60 HOMA IR 60 receiving golimumab 60 Visual Analogue Scale VAS 60 HIV RNA 60 CYP#A# CYP#D# 60 #.#mg/dL 60 μg kg 60 lispro 60 serum electrolytes 60 lopinavir r arm 60 dose proportionality 59 NPH insulin 59 MADRS score 59 3mg/kg 59 Primary endpoints 59 Fulvestrant 59 gadolinium enhancing lesions 59 SGRQ 59 4mg/kg 59 intravascular hemolysis 59 FOLFOX6 59 PCWP 59 bronchodilation 59 solifenacin 59 IPSS 59 ATACAND 59 #mg/day [002] 59 Pain Intensity 59 tolvaptan 59 achieved ACR# 59 retinal thickness 59 ADCS CGIC 59 CDAI score 59 moderate hepatic impairment 59 ALT normalization 59 Secondary endpoints included 59 echocardiographic parameters 59 azilsartan medoxomil 59 Brief Psychiatric 59 glycosylated hemoglobin HbA1c 59 sUA 59 racemic albuterol 59 Tiotropium 59 posttreatment 59 IBDQ 59 achieved CCyR 59 Subgroup analysis 59 aspartate aminotransferase AST 59 UPDRS 59 BENICAR 59 mg BID 59 Double Blind Randomized 59 #mg/m# [002] 59 Endocrine Therapy 59 EDARBI 59 iPTH 59 aspartate aminotransferase 59 budesonide pMDI 59 R# #mg BID 59 serum cortisol 58 TNSS 58 postintervention 58 ALVESCO 58 tiotropium 58 Pharmacodynamic 58 Severity Index PASI 58 somatostatin analog 58 left ventricular diastolic 58 alfa 2a 58 #mg/kg [002] 58 Adjuvant Treatment 58 Forced expiratory volume 58 insulin detemir 58 administered subcutaneously 58 Endothelial function 58 ribavirin RBV 58 TLUS 58 Capsules CII 58 AGILECT R 58 aminotransferases 58 lipoprotein Lp 58 CI -#.# 58 CIMZIA ™ 58 AST ALT 58 Secondary efficacy endpoints 58 REYATAZ r arm 58 Secondary endpoints 58 creatinine ratio 58 CIBIC plus 58 glycosylated hemoglobin levels 58 Viral load 58 ug kg 58 prospectively stratified 58 Betaferon R 58 HBeAg negative patients 58 Non inferiority 58 ritonavir boosted 58 placebo fluoxetine 58 mild renal insufficiency 58 secondary efficacy endpoint 58 Scale PANSS 58 mL/min/#.# m 2 58 YMRS 58 lactate dehydrogenase LDH 58 certolizumab 58 salivary cortisol 58 tirofiban 58 platelet aggregation IPA 58 1mg 2mg 58 mg qd 58 SGPT 58 liver histology 58 baseline FEV 58 -#.# ± [002] 58 FEV1 forced expiratory 58 serum HBV DNA 58 FFNS 58 Relapsed Multiple Myeloma 58 lispro alone 58 timepoints 58 DASISION study 58 phonophobia 58 urinary N telopeptide 58 methacholine challenge 58 PANSS scores 57 UPDRS motor 57 min -1 57 transaminases 57 NYHA functional class 57 OGTT 57 Metastatic Renal Cell Carcinoma 57 headache nasopharyngitis 57 nausea photophobia 57 Castration Resistant Prostate Cancer 57 #mg doses [002] 57 #mg BID [001] 57 Hormone Refractory Prostate Cancer 57 prednisone prednisolone plus 57 hematologic parameters 57 Cystatin C 57 Newly Diagnosed Multiple Myeloma 57 Pharmacokinetic 57 epoetin alpha 57 Symptom severity 57 Plaque Psoriasis 57 Patency 57 AUC0 57 pulmonary capillary wedge 57 relapsed MM 57 candesartan cilexetil 57 #.#/#.# mmHg [001] 57 CNS LS 57 IV bolus 57 Sustained virologic response 57 Inventory BPI 57 SPIRIT FIRST 57 Secondary endpoints include 57 glomerular filtration rate 57 Endothelial Function 57 scores TNSS 57 PROCTOCORT ® Suppository Hydrocortisone 57 HDRS 57 BENICAR HCT 57 baseline HbA1c 57 Dose Escalation 57 undetectable HBV DNA 57 moderate hepatic insufficiency 57 activated partial thromboplastin 57 laboratory abnormalities 57 MCyR 57 Lantus ® 57 REYATAZ r 57 Cardiac Resynchronization 57 GAMMAGARD 57 fluticasone salmeterol 57 mg QD 57 Pegasys ® 57 creatinine clearance 57 GERD symptom 57 DAS# remission 57 serum leptin 57 eNO 57 #mg/m# [001] 57 urine albumin 57 EPIVIR 57 ACR# ACR# 57 atazanavir ritonavir 57 linaclotide treated 57 RECIST Response Evaluation Criteria 57 bronchial reactivity 57 Qmax 57 CCyR 57 HbA1c levels 57 q#h 57 clinically meaningful reductions 57 cardiovascular calcification 57 Main Outcome Measures 57 unfractionated heparin UFH 57 brand ciclesonide HFA 57 nasal symptom 57 glycated hemoglobin HbA1c 57 STELARA ® 57 cEVR 57 Visual acuity 57 tipranavir r 57 oral rivaroxaban 57 Postoperative 57 STRATEGY FOR AN OPEN 57 venlafaxine XR 57 #.#/#.# mm Hg [003] 57 CANCIDAS 57 permanently discontinue Vectibix 57 colesevelam HCl 57 Unfractionated Heparin 57 urinary albumin 57 Adalimumab 57 Monotherapy 57 hour bronchodilation 57 peginterferon alfa 2a 57 Autologous Stem Cell Transplantation 57 clinically meaningful improvement 57 aldosterone antagonists 56 oral antidiabetic medication 56 Mg Uk 56 hemodynamic parameters 56 ispinesib administered 56 Pegylated Liposomal Doxorubicin 56 CTAP# Capsules 56 SBM frequency 56 #μg [001] 56 Treatment Outcome 56 H2RAs 56 hyperphenylalaninemia HPA due 56 pulmonary arterial 56 haematologic 56 detectable HCV RNA 56 apolipoprotein B 56 serum sodium 56 placebo PBO 56 p = NS 56 PREZISTA r arm 56 mediated dilation 56 Severity MSCS score 56 mL kg 56 methotrexate monotherapy 56 CRESTOR #mg 56 dual endothelin receptor antagonist 56 atorvastatin #mg 56 flow mediated dilation 56 Telbivudine 56 Angiographic 56 repeat paracentesis 56 fractional shortening 56 preintervention 56 CK MB 56 pharmacokinetic characteristics 56 Montgomery Åsberg Depression 56 hemoglobin A1c HbA1c 56 serum phosphate levels 56 Antitumor Activity 56 serum aminotransferase levels 56 INCB# [003] 56 Tolerability 56 plasma concentrations 56 BYSTOLIC 56 subcutaneous enoxaparin 56 serum phosphate 56 serum concentrations 56 ADCS ADL 56 CK # plasma concentrations 56 Scale EDSS 56 mU liter 56 amisulpride 56 Visual Analog Scale 56 LEXIVA r 56 concentration Cmax 56 metabolic parameters 56 Eur J Endocrinol 56 Naive Patients 56 Mg Usa 56 mg simvastatin 56 SGOT 56 urinary calcium excretion 56 albumin excretion rate 56 fraction LVEF 56 elevated transaminases 56 Primary Endpoint 56 hemodynamically significant 56 plus COPEGUS 56 spontaneous bowel movements 56 postprocedure 56 Ejection Fraction 56 Randomized Double blind 56 ‰ ¥ 56 Renal Impairment 56 Microalbuminuria 56 Apidra ® 56 exploratory endpoints 56 albumin creatinine ratio 56 bivalirudin monotherapy 56 placebo p = 56 Treatment Naive Patients 56 sustained virologic response 56 mg eq 56 Albuminuria 56 Median PFS 56 nicardipine 56 plasma HCV RNA 56 Left Ventricular Ejection Fraction 56 isoprostane 56 MADRS 56 fasting blood glucose 56 eszopiclone 56 Atomoxetine 56 fosbretabulin 56 triiodothyronine 56 mg ustekinumab 56 INVEGA ® 56 Key secondary endpoints 56 TIMP 1 56 PSA nadir 56 Solid Tumors criteria 56 Q2W 56 dapagliflozin plus 56 certolizumab pegol 56 secondary endpoint 56 exhaled NO 56 r hGH 56 brachial artery flow 56 dactylitis 56 IELT 56 left ventricular systolic 56 estimated GFR 56 HbA 1c 56 estimated glomerular filtration 56 aminotransferase ALT 56 Hemoglobin A1c 56 mTSS 56 CDAI 56 IFN beta 56 Statistically Significant 56 serum lipid levels 56 PROMACTA 56 Ceplene/IL-2 56 See CLINICAL PHARMACOLOGY 56 administered cetrorelix 56 -5 -6 56 #mg #mg #mg [003] 56 serum phosphorus 56 Natalizumab 56 abnormal p# biomarker 56 Cmax 56 bone marrow reticulin deposition 56 hemoglobin Hb 56 urinary excretion 56 Xalatan R 56 peginterferon alfa 2a #KD 56 pegylated interferon peg IFN 56 lopinavir r 56 CK # plasma 56 Negative Symptom Scale 56 β blockers 56 steroid dexamethasone 56 Meets Primary Endpoint 56 dizziness nausea diarrhea 56 metabolite concentrations 56 Free Survival PFS 56 Desvenlafaxine Succinate 56 Sleep Disturbances 56 insulin degludec 56 salmeterol fluticasone 56 complete cytogenetic response 56 Score TOS 55 Histologic 55 linoleic acid LA 55 glycated hemoglobin levels 55 UACR 55 mL sec 55 sitaxsentan 55 virological response 55 ULORIC 55 Ocular Surface Disease 55 APTIVUS r 55 serum testosterone 55 PreCISe 55 adalimumab 55 inhaled budesonide 55 instantaneous TNSS 55 hypokalemia 55 serum clusterin levels 55 Hamilton Anxiety Scale 55 plasma renin activity 55 Posaconazole 55 VELCADE melphalan 55 oxycodone IR 55 IFN α 55 oral FTY# 55 plasma leptin 55 AUA Symptom Score 55 PRADAXA #mg 55 response CCyR 55 mcg kg 55 BARACLUDE ® 55 serologically active patients 55 corrected QT interval 55 rosuvastatin #mg 55 intermittent dosing 55 WOMAC TM 55 plus dexamethasone 55 apnea hypopnea 55 primary efficacy endpoint 55 IR prednisone 55 log# copies mL 55 creatine kinase 55 triglyceride TG 55 lymphopenia 55 #Gy 55 leukocyte count 55 SpO 2 55 Renal Insufficiency 55 dosing interval 55 tapentadol IR 55 secondary endpoints 55 symptomatic VTE 55 intraocular pressure IOP 55 Mycophenolate Mofetil 55 Mean Symptom Complex 55 SPRYCEL ® 55 TAXUS p value 55 Endarterectomy 55 biphasic insulin aspart 55 FDA defined valvulopathy 55 cTnI 55 fasting insulin 55 Acute Ischemic Stroke 55 CLARITY study 55 REYATAZ R 55 cyclosporine tacrolimus 55 LVEF 55 hemorrhagic cerebrovascular events 55 serum magnesium potassium 55 hemoglobin A1c levels 55 S#.# [006] 55 Peginterferon Alfa 2a 55 annualized relapse 55 serum creatinine levels 55 lipid parameters 55 non menstrual pelvic 55 P = .# 55 plasma pharmacokinetics 55 #-#,# mg 55 secondary efficacy endpoints 55 Patients Receiving 55 liposome injection 55 lactate dehydrogenase 55 intravenous bolus 55 SCIg 55 Decitabine 55 Remission Maintenance 55 EGFR TKI 55 serum urate levels 55 arterial oxygen saturation 55 Prostate specific antigen 55 Subgroup Analysis 55 tapentadol ER 55 #mg BID [003] 55 alpha 2a 55 teriflunomide 55 FOLPI 55 rFSH 55 eosinophil count 55 GI motility 55 % Confidence Interval 55 ischemia driven 55 metabolic alkalosis 55 CIMZIA TM certolizumab pegol 55 irbesartan 55 serum uric acid 55 Is Well Tolerated 55 demonstrated statistically significant 55 ibandronate 55 ara C 55 intact parathyroid hormone 55 #mg QD [002] 55 HER2 expression 55 #mg dose [002] 55 analgesic efficacy 55 lopinavir ritonavir plus 55 AZT zidovudine Retrovir 55 postmenopausal osteoporotic women 55 memantine HCl 55 Randomized Double Blind 55 #mg dose [001] 55 Heart Failure Patients 55 Phase 2a Trial 55 TDF FTC 55 virologic suppression 55 bronchoconstriction 55 Ambulatory Blood Pressure 55 Hazard Ratio HR 55 dosed intravenously 55 Functional Outcomes 55 Randomized Clinical Trials 55 total cholesterol triglycerides 55 sweat chloride 55 biochemical relapse 55 Neuropsychiatric Inventory NPI 55 myocardial viability 55 Endothelial dysfunction 55 μmol L 55 PREZISTA ritonavir 55 pulmonary exacerbations 55 nondiabetic patients 55 DAS# CRP 55 mcg albinterferon alfa 2b 55 Treated Patients 55 FOR AN OPEN 55 Novel Inhibitor 55 Bronchodilator 55 6MW distance 55 Tipranavir 55 DLTs 55 timepoint 55 Cardiorespiratory fitness 55 troponin T 55 sUA levels 55 Negative Symptoms 55 Non Responders 55 macular thickness 55 daily Infergen 55 kg -1 55 REMINYL ® 55 endoscopic remission 55 Treatment Diabetic Retinopathy 55 expiratory flow 55 nadolol 55 walk distance 6MWD 55 viral kinetics 55 overt nephropathy 55 Persistent Sleep 55 inotropic agents 55 KAPVAY 55 PSADT 55 Pharmacodynamics 55 #ug [002] 55 mg BID dose 55 Physical Function 55 Raptiva r 55 HBV DNA levels 55 Tumor shrinkage 55 fructosamine 55 PEGylated anti 55 Fasting plasma glucose 55 IU mL 55 dehydroepiandrosterone sulfate 55 LV ejection fraction 55 Dyspnea 54 AA Amyloidosis 54 #.#mg/kg [002] 54 posttransplant 54 total cholesterol LDL 54 Platelet counts 54 Interferon beta 1a 54 Randomized Phase II 54 CSBM 54 Solid Tumours 54 HDL Cholesterol 54 β blocker 54 clinically meaningful improvements 54 baseline serum creatinine 54 TO AVOID PREGNANCY WHILE 54 Intravitreal 54 Insulin sensitivity 54 Major Adverse Cardiac 54 QTc intervals 54 Betaferon ® 54 CPAP adherence 54 esomeprazole 54 natriuresis 54 HbA1c 54 Insulin Glargine 54 orthostatic 54 ANCOVA 54 urinary sodium excretion 54 periprocedural 54 EURIDIS 54 Hemodialysis Patients 54 IV DHE 54 Ann Oncol 54 Single Dose 54 5 Fluorouracil 54 titrated glipizide 54 seroprotection 54 seropositive patients 54 0 document.write 54 statistical significance p 54 Fibromyalgia Impact Questionnaire 54 COPAXONE R 54 log# IU mL 54 Skin sterol 54 uM 54 non squamous histology 54 LymphoStat B belimumab 54 limiting toxicity 54 CRP marker 54 Randomized Evaluation 54 pmol L 54 trandolapril 54 GSK# [001] 54 plus prednisone 54 interleukin IL -6 54 Predict Risk 54 PLX STROKE targeting 54 PEGINTRON TM 54 immunostaining 54 zonisamide SR 54 systolic BP 54 Inhaled Nitric Oxide 54 Showed Significant 54 hsCRP levels 54 clinical worsening suicidality 54 detemir 54 Relapsing Remitting Multiple Sclerosis 54 EDEMA4 trial 54 Lucentis monotherapy 54 mucosal healing 54 Chronic Hepatitis C 54 statistically significant p = 54 Morning Sentence Fragments 54 Chemophase 54 #q# deletion syndrome 54 adjunctive placebo 54 PANSS 54 pyrexia mucositis sepsis febrile 54 Index CDAI score 54 humanized interleukin 6 54 Thrombolysis 54 Hepatotoxicity 54 oral glucose tolerance 54 Prognostic Value 54 mg m² 54 evaluating tivozanib 54 liver enzymes ALT 54 Placebo Controlled Study 54 NLX P# 54 Diastolic 54 Depressive Symptoms 54 Apgar scores 54 Dose Ranging 54 pretreatment baseline 54 Demonstrates Positive 54 antiretroviral naive 54 HbA1C levels 54 Arterial stiffness 54 alicaforsen enema 54 Peginterferon 54 COMBIVIR 54 aPTT 54 specific antigen PSA 54 antibody titer 54 NIHSS 54 Severe Asthma 54 metastatic malignant 54 vecuronium 54 Novel Oral 54 sustained virological response 54 stage IIIb IV 54 indigo# 54 intravenous dosing 54 mcg Albuferon 54 serum ALT 54 PREZISTA r 54 Free Full Text 54 cytogenetic response 54 primary efficacy endpoints 54 kilometers FTK 54 pharmacokinetic parameters 54 TURBT 54 PTH analog 54 alteplase 54 intima media thickness IMT 54 affective psychosis 54 mITT population 54 infliximab monotherapy 54 Thyroid Hormone 54 hypophosphatemia 54 mEq L 54 PEG IFN 54 R pioglitazone HCl 54 HBeAg positive patients 54 NSTE ACS 54 LPV r 54 Knee Osteoarthritis 54 Stent Restenosis 54 CR nPR 54 Hypertensive adverse reactions 54 Orthostatic Hypotension 54 forced expiratory volume 54 Demonstrates Sustained 54 antipsychotic efficacy 54 #.#mmol L [002] 54 carotid intima media 54 Univariate 54 olanzapine LAI 54 thyrotropin 54 Adefovir 54 mg tid 54 dose atorvastatin 54 XIENCE V PROMUS Stent 54 akinesia 54 CrCl 54 Joshua Coppins NZL Aprilia 54 Zorbtive TM 54 glulisine 54 BARACLUDE r 54 Kidney Transplant Patients 54 sinus rhythm 54 oral levofloxacin 54 DAS# scores 54 alpha blocker 54 EDSS scores 54 mesalamine granules 54 #.#g/day 54 radiographic progression 54 Baseline characteristics 54 PaO 2 54 Moli# 54 fludarabine cyclophosphamide 54 plus glimepiride 54 DAS# [002] 54 protein excretion 54 Metastatic Prostate Cancer 54 neurocognitive function 54 polysomnography PSG 54 prespecified secondary 54 T2 lesion volume 54 achieved PASI 54 Hypotension 54 amprenavir 54 adefovir 54 plasma creatinine 54 stomatitis pharyngitis 54 hepatic function 54 dose escalation phase 54 hours postdose 54 titrated 54 TOP2A gene 54 #OHD levels 54 QTc 54 mineral density BMD 54 pulmonary artery pressure 54 undetectable HCV RNA 54 INCB# [001] 54 EBMT criteria 54 TWYNSTA 54 Aeolus Pharmaceuticals Announces 54 urinary cortisol 54 CSBMs 53 postprandial blood glucose 53 statistically significant p 53 Nicotine Vaccine 53 VAPRISOL 53 orthostatic blood 53 bronchial hyperresponsiveness 53 hepatic enzymes 53 Induction Chemotherapy 53 pharmacodynamic PD 53 bronchodilatory 53 saline placebo 53 Pioglitazone 53 serum estradiol 53 UPDRS Part III 53 0 document.write sline 53 Systolic 53 fasting serum 53 Acute Myocardial Infarction 53 Pharmacokinetics PK 53 C Reactive Protein 53 Pred Forte 53 apnea hypopnea index 53 Hb A1C 53 CombAT 53 follicle stimulating hormone FSH 53 locomotor activity 53 Clinical Outcome 53 Flu Cy 53 WOMAC pain 53 pg ml 53 RoACTEMRA 53 Darunavir 53 bronchoalveolar lavage 53 Suppository Hydrocortisone Acetate Rectal 53 Stent Thrombosis 53 Improves Outcomes 53 Neupro R 53 blood Phe 53 plus Copegus 53 TMC# r 53 Nebulized 53 adefovir treated 53 -#.# ± [001] 53 Interferon beta 1b 53 Myelodysplastic Syndrome MDS 53 plasma cortisol 53 adenotonsillectomy 53 ACE Inhibitor 53 Vasomotor Symptoms 53 plasma lipids 53 Capesaris 53 CHAMPION PCI 53 Events MACE 53 hemoglobin concentrations 53 Intracoronary 53 K ras mutations 53 atrioventricular block 53 resected pancreatic cancer 53 mg kg hr 53 urinary albumin excretion 53 x ULN 53 Complicated Skin 53 Selective Cardiac Myosin 53 rizatriptan 53 RLS symptoms 53 Demonstrates Efficacy 53 PegIFN RBV 53 Treat Heart Failure 53 serum thyroglobulin 53 Nephrol Dial Transplant 53 dyspnea 53 microgram kg 53 ACR Pedi 53 Plasma concentrations 53 urate lowering therapy 53 fibrinolysis 53 pegylated liposomal doxorubicin 53 TNFalpha 53 mucociliary clearance 53 antiretroviral naïve 53 #.#mmHg 53 eplerenone 53 Selective Cardiac Myosin Activator 53 F FDG PET 53 dose pravastatin 53 Traficet EN 53 nmol 53 reduce serum phosphate 53 catheter occlusion 53 HIV HCV coinfected 53 AGTR1 53 Main Outcome Measure 53 Solid Tumors 53 nighttime awakenings 53 Monitoring ABPM 53 Hypercholesterolemia 53 QD dosing 53 luteinising hormone LH 53 neurologic progression 53 blood glucose concentrations 53 CINQUIL 53 #:#-# Abstract Free [009] 53 Prevent Strokes 53 Virologic 53 transaminase elevations 53 Hepatitis C Genotype 53 hemodynamics 53 subcutaneously administered 53 serum IGF 53 Kaplan Meier analysis 53 binary restenosis 53 IL#B 53 Sandostatin R 53 Therapy Reduces 53 gastric pH 53 Pharmacokinetic Study 53 Tbone Slickens 53 intermittent hemodialysis 53 ADHD Rating Scale 53 contractile function 53 Carbidopa Levodopa 53 nmol liter 53 elevated ALT 53 Achieves Primary Endpoint 53 perioperatively 53 WE WILL CONTINUE TO 53 Renal Function 53 lactulose 53 budesonide 53 abdominal pain abdominal discomfort 53 symptom severity 53 coadministration 53 ALT elevation 53 Denufosol 53 tHcy concentrations 53 mg subcutaneous 53 nonfasting 53 Am J Gastroenterol 53 hemagglutination inhibition HAI 53 FDG uptake 53 Anticancer Drugs 53 elevated creatinine 53 vapreotide acetate 53 serum calcium 53 mcg mL 53 clomipramine 53 Response Evaluation Criteria 53 p = .# [002] 53 LOCF 53 Proc Am Soc 53 = #.#-#.# 53 Rating Scale UPDRS 53 HCV RESPOND 2 53 Bosutinib 53 #mg BID [002] 53 Fasting glucose 53 VKORC1 53 pharmacodynamic effects 53 RAPAFLO R 53 Long Term Efficacy 53 placebo controlled dose escalation 53 Score DAS